752 related articles for article (PubMed ID: 26568117)
1. Manipulating regulatory T cells: a promising strategy to treat autoimmunity.
Zhang D; Tu E; Kasagi S; Zanvit P; Chen Q; Chen W
Immunotherapy; 2015; 7(11):1201-11. PubMed ID: 26568117
[TBL] [Abstract][Full Text] [Related]
2. Treatment With FoxP3+ Antigen-Experienced T Regulatory Cells Arrests Progressive Retinal Damage in a Spontaneous Model of Uveitis.
Liu YH; Mölzer C; Makinen K; Kamoi K; Corbett CLC; Klaska IP; Reid DM; Wilson HM; Kuffová L; Cornall RJ; Forrester JV
Front Immunol; 2020; 11():2071. PubMed ID: 33013877
[TBL] [Abstract][Full Text] [Related]
3. Treg Enhancing Therapies to Treat Autoimmune Diseases.
Eggenhuizen PJ; Ng BH; Ooi JD
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977677
[TBL] [Abstract][Full Text] [Related]
4. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities.
Brusko TM; Putnam AL; Bluestone JA
Immunol Rev; 2008 Jun; 223():371-90. PubMed ID: 18613848
[TBL] [Abstract][Full Text] [Related]
5. Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells.
Kang HK; Liu M; Datta SK
J Immunol; 2007 Jun; 178(12):7849-58. PubMed ID: 17548623
[TBL] [Abstract][Full Text] [Related]
6. Contribution of CD4+CD25+ T cells to the regression phase of experimental autoimmune uveoretinitis.
Sun M; Yang P; Du L; Zhou H; Ren X; Kijlstra A
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):383-9. PubMed ID: 19696173
[TBL] [Abstract][Full Text] [Related]
7. Type 1 diabetes vaccine candidates promote human Foxp3(+)Treg induction in humanized mice.
Serr I; Fürst RW; Achenbach P; Scherm MG; Gökmen F; Haupt F; Sedlmeier EM; Knopff A; Shultz L; Willis RA; Ziegler AG; Daniel C
Nat Commun; 2016 Mar; 7():10991. PubMed ID: 26975663
[TBL] [Abstract][Full Text] [Related]
8. In vivo-generated antigen-specific regulatory T cells treat autoimmunity without compromising antibacterial immune response.
Kasagi S; Zhang P; Che L; Abbatiello B; Maruyama T; Nakatsukasa H; Zanvit P; Jin W; Konkel JE; Chen W
Sci Transl Med; 2014 Jun; 6(241):241ra78. PubMed ID: 24944193
[TBL] [Abstract][Full Text] [Related]
9. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment.
Strauss L; Bergmann C; Szczepanski M; Gooding W; Johnson JT; Whiteside TL
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4345-54. PubMed ID: 17671115
[TBL] [Abstract][Full Text] [Related]
10. Regulating the regulators: Is introduction of an antigen-specific approach in regulatory T cells the next step to treat autoimmunity?
Janssens I; Cools N
Cell Immunol; 2020 Dec; 358():104236. PubMed ID: 33137651
[TBL] [Abstract][Full Text] [Related]
11. Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential.
Masteller EL; Tang Q; Bluestone JA
Semin Immunol; 2006 Apr; 18(2):103-10. PubMed ID: 16458533
[TBL] [Abstract][Full Text] [Related]
12. Regulatory T-cell adoptive immunotherapy: potential for treatment of autoimmunity.
Wright GP; Ehrenstein MR; Stauss HJ
Expert Rev Clin Immunol; 2011 Mar; 7(2):213-25. PubMed ID: 21426259
[TBL] [Abstract][Full Text] [Related]
13. In Vivo Expansion of Antigen-Specific Regulatory T Cells through Staggered Fc.IL-2 Mutein Dosing and Antigen-Specific Immunotherapy.
Pham MN; Khoryati L; Jamison BL; Hayes E; Sullivan JM; Campbell DJ; Gavin MA
Immunohorizons; 2021 Sep; 5(9):782-791. PubMed ID: 34583939
[TBL] [Abstract][Full Text] [Related]
14. Stabilizing human regulatory T cells for tolerance inducing immunotherapy.
He X; Koenen HJ; Slaats JH; Joosten I
Immunotherapy; 2017 Aug; 9(9):735-751. PubMed ID: 28771099
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle-based autoantigen delivery to Treg-inducing liver sinusoidal endothelial cells enables control of autoimmunity in mice.
Carambia A; Freund B; Schwinge D; Bruns OT; Salmen SC; Ittrich H; Reimer R; Heine M; Huber S; Waurisch C; Eychmüller A; Wraith DC; Korn T; Nielsen P; Weller H; Schramm C; Lüth S; Lohse AW; Heeren J; Herkel J
J Hepatol; 2015 Jun; 62(6):1349-56. PubMed ID: 25617499
[TBL] [Abstract][Full Text] [Related]
16. IL-2 contributes to maintaining a balance between CD4+Foxp3+ regulatory T cells and effector CD4+ T cells required for immune control of blood-stage malaria infection.
Berretta F; St-Pierre J; Piccirillo CA; Stevenson MM
J Immunol; 2011 Apr; 186(8):4862-71. PubMed ID: 21389253
[TBL] [Abstract][Full Text] [Related]
17. [Use of regulatory T cells in cellular therapies in autoimmune diseases].
Boursier G; Siri A; de Boysson H
Med Sci (Paris); 2012; 28(8-9):757-63. PubMed ID: 22920878
[TBL] [Abstract][Full Text] [Related]
18. Antigen-Specific Regulatory T Cell Therapy in Autoimmune Diseases and Transplantation.
Selck C; Dominguez-Villar M
Front Immunol; 2021; 12():661875. PubMed ID: 34054826
[TBL] [Abstract][Full Text] [Related]
19. Increased CD4+CD25+Foxp3+ regulatory T cells in tolerance induced by portal venous injection.
He F; Chen Z; Xu S; Cai M; Wu M; Li H; Chen X
Surgery; 2009 Jun; 145(6):663-74. PubMed ID: 19486771
[TBL] [Abstract][Full Text] [Related]
20. The role of FOXP3
Mohr A; Atif M; Balderas R; Gorochov G; Miyara M
Clin Exp Immunol; 2019 Jul; 197(1):24-35. PubMed ID: 30830965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
